Salk researchers found that a drug already approved by the FDA for the treatment of psoriasis deactivates the switch governing the fibrotic response in mouse liver cells, suggesting a potential new therapy
for fibrotic diseases in humans.
Now, in a new study published in the journal Cell, scientists at the Salk Institute for Biological Studies have discovered that a synthetic form of vitamin D, calcipotriol (a drug already approved by the FDA for the treatment of psoriasis), deactivates the switch governing the fibrotic response in mouse liver cells, suggesting a potential new therapy
for fibrotic diseases in humans.
Not exact matches
The compound is now in phase II clinical trials
for diabetic nephropathy and is being explored in other
fibrotic diseases.
«In the future, these results could also lead to new therapeutic options
for the treatment of other
fibrotic diseases.»
«There could be potential long - term therapeutic treatments that could arise from this new knowledge, which can be explored
for the treatment of additional
fibrotic disorders including kidney
disease.»
Fibrotic diseases, such as chronic kidney
disease and failure, lung
disease, heart failure and cirrhosis of the liver, are estimated to be responsible
for up to 45 percent of deaths in the developed world.
Previously Dr. Martini worked at Shire plc in Lexington, Mass., as Senior Director of Discovery Biology and Translational Research, Mass., focusing on
fibrotic diseases of muscle, kidney, skin, lung, bone marrow and metabolic liver
diseases, with particular emphasis on different therapeutic modalities
for pathway modulation.
NorthSea Therapeutics develops therapeutics
for NASH and other metabolic, inflammatory and
fibrotic diseases.